Thymoma and Thymic Carcinoma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Thymoma and thymic carcinoma are rare thymic epithelial tumours (TETs) arising from the thymic epithelium of the anterior mediastinum, collectively accounting for less than 1% of all thoracic malignancies. With an annual incidence of approximately 0.15 per 100,000 in the United States, they are among the rarest thoracic tumours. Thymoma is the more common entity (approximately 60-80% of TETs), with generally indolent behaviour and an established association with autoimmune paraneoplastic syndromes, most notably myasthenia gravis (MG) in 30-45% of thymoma patients. Thymic carcinoma is a distinct, more aggressive high-grade epithelial malignancy with poor prognosis, no associated autoimmune syndromes, and different molecular characteristics. Both tumours occur predominantly in adults aged 40-60 years, with no strong sex predilection for thymoma. The WHO Classification of Thymic Tumours (2015) classifies thymomas by histological type (A, AB, B1, B2, B3) based on the morphology of neoplastic epithelial cells and the lymphocytic composition of the tumour stroma, while thymic carcinoma (TC, Type C historically) is a separate high-grade entity. Masaoka-Koga surgical staging — based on the extent of capsular invasion and spread — remains the primary staging system guiding adjuvant therapy and prognosis.

The aetiology of thymoma and thymic carcinoma is poorly understood, and the majority of cases are sporadic with no identifiable environmental or infectious risk factors. Unlike most malignancies, thymoma is uniquely characterised by its intimate association with autoimmune paraneoplastic conditions — a phenomenon attributed to the thymus's central role in T-cell education and the disruption of central tolerance mechanisms by thymoma cells. GTF2I mutations are the most common somatic mutation in thymoma, particularly enriched in the indolent Type A and AB subtypes (found in approximately 80% of Type A), conferring a more favourable clinical behaviour and distinct molecular identity. Thymic carcinoma harbours a different mutational landscape including KIT mutations (approximately 10%), CDKN2A deletions, and various driver copy number alterations. Multiple endocrine neoplasia type 1 (MEN1) syndrome predisposes to thymic NETs (carcinoid tumours of the thymus) but not to true thymoma. Prior radiotherapy to the mediastinum is a documented risk factor. The immunological dysregulation of thymoma manifests as aberrant intratumoral T-cell selection, generating autoreactive T-cells that escape negative selection and drive anti-AChR antibody production (myasthenia gravis), anti-erythropoietin antibodies (pure red cell aplasia), and other autoimmune phenomena including polymyositis, SLE, and Good's syndrome (hypogammaglobulinaemia).

Approximately 30-40% of thymomas are detected incidentally on chest imaging performed for unrelated reasons and are asymptomatic at diagnosis. When symptoms occur, they arise from mass effect in the anterior mediastinum or from associated autoimmune paraneoplastic syndromes. Local mass effect produces chest pain, persistent cough, and dyspnoea; superior vena cava syndrome (facial oedema, arm oedema, dilated neck veins, plethora) occurs with advanced disease invading or compressing the SVC. Myasthenia gravis is the most important associated autoimmune condition: symptoms include ptosis (drooping eyelid), diplopia (double vision), bulbar weakness manifesting as dysarthria (slurred speech) and dysphagia, proximal limb weakness with fatigability, and respiratory muscle weakness that can precipitate myasthenic crisis requiring ventilatory support. Pure red cell aplasia presents as severe normochromic normocytic anaemia refractory to iron supplementation. Good's syndrome (thymoma-associated hypogammaglobulinaemia) causes recurrent bacterial infections. Constitutional symptoms — fever, weight loss, and night sweats — are more common with thymic carcinoma and correlate with more aggressive disease biology. Pleural or pericardial effusions indicate Stage IVa dissemination.

CT of the chest with intravenous contrast is the primary diagnostic imaging modality, demonstrating an anterior mediastinal mass with lobulated contours, calcification in approximately 20%, and evidence of capsular invasion or adjacent organ involvement that determines resectability and Masaoka-Koga stage. MRI of the thorax provides superior soft tissue characterisation and is particularly useful for assessing pericardial invasion, SVC involvement, and vascular anatomy when CT findings are equivocal. PET/CT is not routinely recommended for thymoma staging but may detect distant metastases in suspected thymic carcinoma. Percutaneous CT-guided core needle biopsy or thoracoscopic (VATS) biopsy provides tissue diagnosis and WHO histological classification — critical for distinguishing thymoma types from thymic carcinoma, lymphoma, and germ cell tumour. Anti-acetylcholine receptor antibody (anti-AChR Ab) testing, electromyography, and repetitive nerve stimulation confirm myasthenia gravis. Serum immunoglobulins assess for Good's syndrome. Serological evaluation for other autoimmune conditions (ANA, anti-dsDNA, rheumatoid factor) is recommended. Masaoka-Koga surgical staging (Stage I-IVb) is determined intraoperatively and on the surgical pathology specimen; it directly determines adjuvant therapy and prognosis.

Complete surgical thymectomy (complete resection of the thymus gland and all associated perithymic fat) is the cornerstone of curative treatment for resectable thymoma and thymic carcinoma, and additionally improves or resolves myasthenia gravis in many patients. Surgical approaches include median sternotomy (traditional standard) and minimally invasive approaches (VATS or robotic-assisted thoracoscopic surgery, RATS) for Stage I-II thymomas; open sternotomy for locally advanced disease requiring en bloc resection of adjacent structures. For Masaoka-Koga Stage I thymoma, complete resection alone achieves cure in the majority without adjuvant therapy. Stage II requires multidisciplinary discussion regarding adjuvant radiotherapy — EBRT at 45-50 Gy — particularly for B2 and B3 histological types or capsular breach at resection margins. Stage III and IVa: induction (neoadjuvant) cisplatin-based chemotherapy (CAP: cisplatin, doxorubicin, cyclophosphamide; or carboplatin/paclitaxel) is given before attempted resection to reduce tumour bulk and improve R0 resection rates; adjuvant radiotherapy follows resection. Unresectable or metastatic thymoma and thymic carcinoma: cisplatin-based chemotherapy (CAP regimen, or carboplatin-paclitaxel) as first-line; sunitinib and lenvatinib show anti-tumour activity in refractory thymoma. Pembrolizumab is FDA-approved specifically for unresectable or metastatic thymic carcinoma (objective response rate approximately 22-23% in KEYNOTE-482); it should be used with extreme caution in thymoma due to the high risk of severe immune-related adverse events in patients with pre-existing autoimmune conditions.

There are currently no established preventive measures or evidence-based screening recommendations for thymoma or thymic carcinoma in the general population, given the rarity of these tumours, the poorly understood aetiology, and the absence of identifiable high-risk groups beyond sporadic case occurrence. No dietary, lifestyle, or pharmacological interventions have been demonstrated to reduce thymic tumour risk. Radiation exposure to the mediastinum — a known risk factor for thymic tumour development — should be minimised in clinical settings where radiotherapy is planned for adjacent mediastinal structures, including in the treatment of Hodgkin lymphoma and other thoracic tumours. Individuals with multiple endocrine neoplasia type 1 (MEN1) syndrome should undergo regular thoracic imaging surveillance for thymic NETs (carcinoid tumours), which are a recognised but uncommon manifestation of MEN1; whole-body MRI or CT surveillance programmes covering the chest are included in MEN1 management guidelines. Patients with established thymoma who develop new autoimmune symptoms should undergo prompt reassessment for disease recurrence or progression, as new autoimmune phenomena in a thymoma patient may be triggered by tumour activity. Monitoring for and treating associated autoimmune conditions (myasthenia gravis, pure red cell aplasia) is an important component of supportive care that preserves quality of life during and after treatment.

Given the association of thymoma with potentially life-threatening autoimmune conditions, specific symptom constellations warrant urgent medical evaluation. Any adult experiencing new-onset drooping of one or both eyelids (ptosis), double vision (diplopia), progressive difficulty swallowing or speaking, or limb weakness that worsens with repeated use and partially improves with rest should be evaluated urgently for myasthenia gravis. A myasthenic crisis — acute respiratory muscle weakness causing breathlessness, difficulty breathing, or inability to swallow — is a medical emergency requiring immediate hospital admission and intensive care evaluation. Any individual diagnosed with myasthenia gravis should have a thoracic CT scan to exclude an underlying thymoma, as the two are associated in approximately 10-15% of MG cases. Unexplained anterior chest pain or persistent cough in the absence of respiratory infection, particularly in a middle-aged adult with no obvious cardiac or pulmonary cause, requires chest imaging to exclude an anterior mediastinal mass. Recurrent bacterial infections, particularly in a patient with an anterior mediastinal mass, should prompt immunoglobulin testing for Good's syndrome. Anaemia that is disproportionate to clinical features and unresponsive to iron therapy requires investigation for pure red cell aplasia and — in that context — evaluation for associated thymoma. Patients with known thymoma should follow their scheduled imaging surveillance for recurrence, particularly as thymoma may recur 10-20 years after initial treatment.

Thymoma Masaoka Stage I: 5-year OS approximately 95-100%. Stage II: approximately 85-90%. Stage III: approximately 70%. Stage IVa/b: approximately 50%. Complete surgical resection is the most important prognostic factor. Thymic carcinoma: 5-year OS approximately 30-50% even after resection, reflecting its more aggressive biology. Myasthenia gravis may persist or worsen after thymectomy in some patients and requires ongoing neurological management. The prognosis for Thymoma and Thymic Carcinoma: Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.